Reduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 4048-4053

  Dutta, Noton K ^a   Pinn, Michael L ^a   Karakousis, Petros C ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN; THIORIDAZINE; NEUROLEPTIC AGENT; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL LOAD; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG HALF LIFE; DRUG RESISTANT TUBERCULOSIS; LUNG PARENCHYMA; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MOUSE; MUTANT; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; DRUG REPOSITIONING; FEMALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

ANIMALS; ANTIPSYCHOTIC AGENTS; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; DRUG REPOSITIONING; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; ISONIAZID; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; THIORIDAZINE; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84903159392     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02981-14     Document Type: Article

References (41)

1. Abubakar I, Zignol M, Falzon D, Raviglione M, Ditiu L, Masham S, Adetifa I, Ford N, Cox H, Lawn SD, Marais BJ, McHugh TD, Mwaba P, Bates M, Lipman M, Zijenah L, Logan S, McNerney R, Zumla A, Sarda K, Nahid P, Hoelscher M, Pletschette M, Memish ZA, Kim P, Hafner R, Cole S, Migliori GB, Maeurer M, Schito M. 2013. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect. Dis. 13:529-539. http://dx.doi.org/10.1016/S1473- 3099(13)70030-6.
2. Mazumdar K, Dastidar SG, Park JH, Dutta NK. 2009. The antiinflammatory non-antibiotic helper compound diclofenac: an antibacterial drug target. Eur. J. Clin. Microbiol. Infect. Dis. 28:881-891. http://dx.doi.org/10.1007/s10096-009- 0739-z.
3. Dutta NK, Karakousis PC. 2012. Tuberculosis chemotherapy: present situation, possible solutions, and progress towards a TB-free world. Indian J. Med. Microbiol. 30:261-263. http://dx.doi.org/10.4103/0255-0857.99481.
4. Louw GE, Warren RM, Gey van Pittius NC, Leon R, Jimenez A, Hernandez-Pando R, McEvoy CR, Grobbelaar M, Murray M, van Helden PD, Victor TC. 2011. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am. J. Respir. Crit. Care Med. 184:269-276. http://dx.doi.org/10.1164/rccm.201011-1924OC.
5. Amaral L, Udwadia Z, Abbate E, van Soolingen D. 2012. The added effect of thioridazine in the treatment of drug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 16:1706-1709. http://dx.doi.org/10.5588/ijtld.12.0616.
6. Choudhuri BS, Bhakta S, Barik R, Basu J, Kundu M, Chakrabarti P. 2002. Overexpression and functional characterization of an ABC (ATP-binding cassette) transporter encoded by the genes drrA and drrB of Mycobacterium tuberculosis. Biochem. J. 367:279-285. http://dx.doi.org/10.1042/BJ20020615. (Pubitemid 35176916)
7. Pasca MR, Guglierame P, Arcesi F, Bellinzoni M, De Rossi E, Riccardi G. 2004. Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 48:3175-3178. http://dx.doi.org/10.1128/AAC.48.8.3175-3178.2004. (Pubitemid 38989198)
8. Kristiansen JE, Thomsen VF, Martins A, Viveiros M, Amaral L. 2010. Non-antibiotics reverse resistance of bacteria to antibiotics. In Vivo 24:751-754. http://iv.iiarjournals.org/content/24/5/751.long.
9. + transport enhance intracellular killing of M. tuberculosis by non-killing macrophages. In Vivo 22:69-75. http://iv.iiarjournals.org/content/ 22/1/69.full.pdf+html.
10. Amaral L, Martins M, Viveiros M. 2007. Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J. Antimicrob. Chemother. 59:1237-1246. http://dx.doi.org/10.1093/jac/dkl500. (Pubitemid 47073342)
11. Adams KN, Takaki K, Connolly LE, Wiedenhoft H, Winglee K, Humbert O, Edelstein PH, Cosma CL, Ramakrishnan L. 2011. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 145:39-53. http://dx.doi.org/10.1016/j.cell.2011.02.022.
12. Black PA, Warren RM, Louw GE, van Helden PD, Victor TC, Kana BD. 2014. Energy metabolism and drug efflux in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 58:2491-2503. http://dx.doi.org/10.1128/AAC.02293-13.
13. Boeree MJ. 2011. Global clinical trials for the treatment of TB with thioridazine. Recent Pat. Antiinfect. Drug Discov. 6:99-103. http://dx.doi.org/10.2174/157489111796064533.
14. Amaral L, Boeree MJ, Gillespie SH, Udwadia ZF, van Soolingen D. 2010. Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int. J. Antimicrob. Agents 35: 524-526. http://dx.doi.org/10.1016/j.ijantimicag.2009.12.019.
15. Thanacoody RH. 2011. Thioridazine: the good and the bad. Recent Pat. Antiinfect. Drug Discov. 6:92-98. http://dx.doi.org/10.2174/157489111796064588.
16. Dutta NK, Mazumdar K, Dastidar SG, Karakousis PC, Amaral L. 2011. New patentable use of an old neuroleptic compound thioridazine to combat tuberculosis: a gene regulation perspective. Recent Pat. Antiinfect. Drug Discov. 6:128-138. http://dx.doi.org/10.2174/157489111796064597.
17. Dutta NK, Mehra S, Kaushal D. 2010. A Mycobacterium tuberculosis sigma factor network responds to cell-envelope damage by the promising anti-mycobacterial thioridazine. PLoS One 5:e10069. http://dx.doi.org/10.1371/ journal.pone.0010069.
18. Machado D, Couto I, Perdigao J, Rodrigues L, Portugal I, Baptista P, Veigas B, Amaral L, Viveiros M. 2012. Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. PLoS One 7:e34538. http://dx.doi.org/10.1371/journal.pone.0034538.
19. Yano T, Li LS, Weinstein E, Teh JS, Rubin H. 2006. Steady-state kinetics and inhibitory action of antitubercular phenothiazines on mycobacterium tuberculosis type-II NADH-menaquinone oxidoreductase (NDH-2). J. Biol. Chem. 281:11456-11463. http://dx.doi.org/10.1074/jbc.M508844200. (Pubitemid 43855400)
20. Viveiros M, Amaral L. 2001. Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines. Int. J. Antimicrob. Agents 17: 225-228. http://dx.doi.org/10.1016/S0924-8579(00)00343-5. (Pubitemid 32229901)
21. van Ingen J, van der Laan T, Amaral L, Dekhuijzen R, Boeree MJ, van Soolingen D. 2009. In vitro activity of thioridazine against mycobacteria. Int. J. Antimicrob. Agents 34: 190-191. http://dx.doi.org/10.1016/j.ijantimicag.2009. 02.015.
22. Martins M, Viveiros M, Kristiansen JE, Molnar J, Amaral L. 2007. The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis. In Vivo 21:771-775. http://iv.iiarjournals.org/content/21/5/771. full.pdf+html.
23. van Soolingen D, Hernandez-Pando R, Orozco H, Aguilar D, Magis-Escurra C, Amaral L, van Ingen J, Boeree MJ. 2010. The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. PLoS One 5:e12640. http://dx.doi.org/10.1371/journal.pone.0012640.
24. Abbate E, Vescovo M, Natiello M, Cufre M, Garcia A, Gonzalez Montaner P, Ambroggi M, Ritacco V, van Soolingen D. 2012. Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine. J. Antimicrob. Chemother. 67: 473-477. http://dx.doi.org/10.1093/jac/dkr500.
25. Sohaskey C. 2011. Latent tuberculosis: is there a role for thioridazine? Recent Pat. Antiinfect. Drug Discov. 6:139-146. http://dx.doi.org/10.2174/ 157489111796064551.
26. Ordway D, Viveiros M, Leandro C, Bettencourt R, Almeida J, Martins M, Kristiansen JE, Molnar J, Amaral L. 2003. Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47:917-922. http://dx.doi.org/10.1128/AAC.47.3. 917-922.2003. (Pubitemid 36254216)
27. Dutta NK, Pinn ML, Zhao M, Rudek MA, Karakousis PC. 2013. Thioridazine lacks bactericidal activity in an animal model of extracellular tuberculosis. J. Antimicrob. Chemother. 68:1327-1330. http://dx.doi.org/10.1093/jac/dkt037.
28. Dutta NK, Illei PB, Peloquin CA, Pinn ML, Mdluli KE, Nuermberger EL, Grosset JH, Karakousis PC. 2012. Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. Antimicrob. Agents Chemother. 56:3726-3731. http://dx.doi.org/10.1128/AAC.00500-12.
29. Dutta NK, Alsultan A, Peloquin CA, Karakousis PC. 2013. Preliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigs. Antimicrob. Agents Chemother. 57:1535-1537. http://dx.doi.org/10.1128/AAC. 01933-12.
30. Nyberg G, Martensson E. 1982. Binding of thioridazine and thioridazine metabolites to serum proteins. An in vitro study. Naunyn Schmiedebergs Arch. Pharmacol. 319:189-196. http://dx.doi.org/10.1007/BF00495864. (Pubitemid 12091312)
31. Ahmad Z, Fraig MM, Bisson GP, Nuermberger EL, Grosset JH, Karakousis PC. 2011. Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections. Antimicrob. Agents Chemother. 55:1527-1532. http://dx.doi.org/10.1128/AAC.01524-10.
32. Reference deleted.
33. Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, Karakousis PC, Grosset JH, Nuermberger EL. 2012. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob. Agents Chemother. 56:4331-4340. http://dx.doi.org/10. 1128/AAC.00912-12.
34. Chakraborty BS, Midha KK, McKay G, Hawes EM, Hubbard JW, Korchinski ED, Choc MG, Robinson WT. 1989. Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: a dose proportionality study. J. Pharm. Sci. 78:796-801. http://dx.doi.org/10.1002/jps.2600781003.
35. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, Kreiswirth BN, Barry CE, Baker WR. 2000. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405:962-966. http://dx.doi.org/10.1038/35016103. (Pubitemid 30435054)
36. Ahmad Z, Nuermberger EL, Tasneen R, Pinn ML, Williams KN, Peloquin CA, Grosset JH, Karakousis PC. 2010. Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. J. Antimicrob. Chemother. 65:729-734. http://dx.doi.org/10.1093/jac/dkq007.
37. Rodrigues L, Wagner D, Viveiros M, Sampaio D, Couto I, Vavra M, Kern WV, Amaral L. 2008. Thioridazine and chlorpromazine inhibition of ethidium bromide efflux in Mycobacterium avium and Mycobacterium smegmatis. J. Antimicrob. Chemother. 61:1076-1082. http://dx.doi.org/10.1093/jac/dkn070. (Pubitemid 351524452)
38. Li XZ, Zhang L, Nikaido H. 2004. Efflux pump-mediated intrinsic drug resistance in Mycobacterium smegmatis. Antimicrob. Agents Chemother. 48:2415-2423. http://dx.doi.org/10.1128/AAC.48.7.2415-2423.2004. (Pubitemid 38823405)
39. Viveiros M, Portugal I, Bettencourt R, Victor TC, Jordaan AM, Leandro C, Ordway D, Amaral L. 2002. Isoniazid-induced transient high-level resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46:2804-2810. http://dx.doi.org/10.1128/AAC.46.9.2804-2810.2002.
40. Musuka S, Srivastava S, Siyambalapitiyage Dona CW, Meek C, Leff R, Pasipanodya J, Gumbo T. 2013. Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners. Antimicrob. Agents Chemother. 57:5870-5877. http://dx.doi.org/10.1128/AAC.00829-13.
41. Salie S, Hsu NJ, Semenya D, Jardine A, Jacobs M. 25 February 2014. Novel non-neuroleptic phenothiazines inhibit Mycobacterium tuberculosis replication. J. Antimicrob. Chemother. http://dx.doi.org/10.1093/jac/dku036.